APSR2026-181

 
Late-Breaking
Submitted
Poster Presentation
 
AP12-004
P81
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1212182-46904-APSR26_Poster AP12-004_433913.pdf
Format: PDF Only
16. Interstitial Lung Disease
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Congjie Wang * Tianjin Medical University Department of Respiratory Medicine, Tianjin Medical University General Hospital Tianjin China
Yan Song - Tianjin Medical University General Hospital Department of Geriatrics, Tianjin Geriatrics Institute Tianjin China
Zhe Chen - Tianjin Medical University General Hospital Department of Geriatrics, Tianjin Geriatrics Institute Tianjin China
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Congjie
Wang
wangcongjie1987@163.com
 
31-40
China
Original Research
Complanatin Alleviates Bleomycin-Induced Pulmonary Fibrosis: A Candidate Compound from Astragalus mongholicus
Maximum 25 words
Abstract Content
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited therapeutic options, particularly affecting the aging population. Novel therapeutic candidates are urgently needed.
Public IPF gene datasets were analyzed to identify fibrosis-related targets. Bleomycin-induced pulmonary fibrosis models were established in vitro and in vivo to evaluate the effects of Complanatin (Com.), a compound derived from Astragalus mongholicus. CYP24A1 inhibitory activity was screened among 23 Astragalus compounds. Fibrotic markers and TGFBR1 signaling were assessed by Western blot, immunohistochemistry, and RNA sequencing. One-way ANOVA with Tukey's test were conducted to assess its therapeutic potential.
Cytochrome P450 24A1 (CYP24A1) was identified as a potential target based on dataset analysis (Fig A). Com. exhibited CYP24A1 inhibitory activity with low cytotoxicity. In fibrotic models, Com. treatment attenuated the expression of multiple fibrosis-associated markers(Fig B). Transcriptomic analysis suggested involvement of pathways related to epithelial-mesenchymal transition.
Complanatin demonstrates protective effects against bleomycin-induced pulmonary fibrosis in preclinical models, supporting its potential as a therapeutic candidate for IPF. Further mechanistic studies are ongoing.
 
 
 
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1212182-37089-Figure3_433914.jpg
JPG or JPEG or PNG format ONLY
Idiopathic pulmonary fibrosis, Complanatin, Astragalus mongholicus, Cytochrome P450 24A1, Epithelial-mesenchymal transition, Preclinical study, Aging
maximum 3 keywords and no abbreviations, separated by commas
 
167